All In Biotech

Drug Trial Radar · NCT05460533

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Phase II Open Label Multicenter Study of Early REinFusion of Tisagenlecleucel to Promote DUrable B-CEll ApLasia in Pediatric and Young Adult Patients With Relapsed/Refractory CD19-Positive B-Cell Acute Lymphoblastic Leukemia (REFUEL)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

30

Actual

Start

Jul 12, 2022

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
Jul 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 day, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.

Conditions

  • B-cell Acute Lymphoblastic Leukemia

Interventions

  • TisagenlecleucelBiological

    Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. decrease the loss of peripheral BCA rateTime frame: 6 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Los Angeles (Data Collection Only)

    Los Angeles, California

  • Stanford University (Data Collection Only)

    Stanford, California

  • Children's Hospital Colorado (Data Collection Only)

    Aurora, Colorado

  • Johns Hopkins University (Data Collection Only)

    Baltimore, Maryland

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cincinnati Children's Hospital Medical Center (Data Collection Only)

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.